Description
(AWP Alliance News) - Galderma Group AG on Thursday said sales grew in the first nine months of 2026, prompting it to revise upwards its full-year guidance.
Galderma shares jumped 5.7% to CHF184.05 in Zurich.
The dermatology products developer said sales in the nine months to September rose 28% to USD4.77 billion from USD3.74 billion a year earlier.
Overall, the Injectable Aesthetics business achieved the highest sales reaching USD2.17 billion, a 16% increase from USD1.87 billion a year earlier.
The Therapeutics Dermatology division had the sharpest growth in the period, rising 68% to USD1.35 billion from USD804.0 million.
Galderma said it now expects 2026 sales to be 22.5% to 23.5% higher than in 2025. In its previous guidance, Galderma forecasted net sales growth between 19% and 21%.
The company confirmed its full-year guidance of core earnings before interest, tax, depreciation and amortisation margin of around 26%.
By Camilla Borri, Alliance News reporter
Comments and questions to newsroom [at] alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
